Working… Menu

Understanding Dexmedetomidine In Infants Post-Operative From Cardiac Surgery (InfantDex)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00573066
Recruitment Status : Completed
First Posted : December 13, 2007
Results First Posted : April 9, 2013
Last Update Posted : April 9, 2013
Information provided by (Responsible Party):
Athena Zuppa, Children's Hospital of Philadelphia

Brief Summary:
This study is being conducted to determine what dexmedetomidine does to the body and in turn, what how the body handles the medication. This medication, for the purpose of this trial, is used as a short-term sedative for infants who are immediately post-operative from cardiac surgery and have a breathing tube and are breathing with the assistance of a mechanical ventilator or breathing machine.

Condition or disease Intervention/treatment Phase
Hypoplastic Left Heart Tetralogy of Fallot Tricuspid Atresia Drug: Dexmedetomidine Phase 1

Detailed Description:
This is a single center, dose escalation study of a single bolus dose of dexmedetomidine followed by a continuous infusion for up to 24 hours in infants who are immediately post-operative from cardiac surgery and require tracheal intubation with mechanical ventilation in the post-operative period. Three bolus doses and infusion doses will be administered to a total of 36 evaluable patients.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 56 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Pharmacokinetics, Pharmacogenetics, and Pharmacodynamics of Dexmedetomidine In Infants Post-Operative From Cardiac Surgery
Study Start Date : May 2004
Actual Primary Completion Date : October 2006
Actual Study Completion Date : October 2006

Arm Intervention/treatment
Experimental: Dosing level
A predetermined dose of Dexmedetomidine
Drug: Dexmedetomidine
Dosage levels: Dose Level 1: Loading dose 0.35mcg/kg and CIVI 0.25mcg/kg/hr Dose Level 2: Loading Dose of 0.7mcg/kg and CIVI 0.5mcg/kg/hr and Dose Level 3: Loading Dose 1 mcg/kg and CIVI 0.75 mcg/kg/hr.
Other Name: Precedex

Primary Outcome Measures :
  1. PK Profile of Dexmedetomidine [ Time Frame: after start of infusion (0.5, 1, 2, 4-6 hours), immediately prior to end of infusion and following end of infusion (0.25, 0.5, 1, 2, 4, 8, 12, 15-18 hours) ]
    This study measured the concentration of dex in the body and used those concentrations to determine how quickly the body metabolizes and eliminates dex(concentration-time or pharmacokinetic profile).The concentration of dex in the body is determined through serial blood sampling while administering dex and following discontinuation.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   1 Month to 24 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must be greater or equal to one month or less than or equal to 24 months of age.
  • Post operative from cardiac surgery with tracheal intubation/mechanical ventilation in the immediate post-op period.
  • Planned tracheal extubation within 24 hours post-operatively.
  • Adequate renal function(1-12 months old creatinine less than or equal to 0.6mg/dL and >12 months to 24 months creatinine < or= to 1.0mg/dL)
  • Adequate liver function(Total bilirubin < or= 1.5mg/dL and ALT 1-12 months < or = to 165 U/L and > 12 months to 24 months < or = to 90 U/L)
  • Isolated heart surgery
  • Informed consent

Exclusion Criteria:

  • Patients who have received another investigational drug within the past 30 days.
  • Receiving continuous infusions of muscle relaxants in the postoperative setting.
  • Patients whoo have a positive blood culture without a subsequent negative culture or other evidence of ongoing serious infection.
  • Patients, who, int he opinion of the investigator may not be able to comply with the safety monitoring requirements of the study.
  • Patients who show signs or symptoms of elevated intracranial pressure.
  • Post-operative hypotension based on age.
  • Preexisting bradycardia based on age.
  • Heart block
  • Weight < 5kg
  • Patients, who in the opinion of the investigator, are not appropriate candidates for an investigational drug study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00573066

Sponsors and Collaborators
Athena Zuppa
Layout table for investigator information
Principal Investigator: Athena Zuppa, MD, MSCE Children's Hospital of Philadelphia
Layout table for additonal information
Responsible Party: Athena Zuppa, Attending Physician, Children's Hospital of Philadelphia Identifier: NCT00573066    
Other Study ID Numbers: 2004-5-3770
First Posted: December 13, 2007    Key Record Dates
Results First Posted: April 9, 2013
Last Update Posted: April 9, 2013
Last Verified: February 2013
Keywords provided by Athena Zuppa, Children's Hospital of Philadelphia:
Postoperative from cardiac surgery
Additional relevant MeSH terms:
Layout table for MeSH terms
Tetralogy of Fallot
Hypoplastic Left Heart Syndrome
Tricuspid Atresia
Heart Defects, Congenital
Cardiovascular Abnormalities
Cardiovascular Diseases
Heart Diseases
Congenital Abnormalities
Heart Valve Diseases
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action